Jpmorgan Chase & CO An2 Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 49 shares of ANTX stock, worth $60. This represents 0.0% of its overall portfolio holdings.
Number of Shares
49
Previous 52
5.77%
Holding current value
$60
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ANTX
# of Institutions
39Shares Held
7.6MCall Options Held
0Put Options Held
0-
Almitas Capital LLC Santa Monica, CA1.43MShares$1.77 Million0.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.28 Million0.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY583KShares$722,6340.62% of portfolio
-
Stonepine Capital Management, LLC Bend, OR544KShares$675,1720.57% of portfolio
-
Landscape Capital Management, L.L.C.495KShares$614,2910.05% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $24.1M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...